DW-5324

DW-5324 is an oral formulation of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, currently in preclinical development by Daewon Pharm in collaboration with Asan Medical Center. The drug is designed to treat endocrine disorders, specifically type 2 diabetes and obesity. By acting as a GLP-1 receptor agonist, it enhances glucose-dependent insulin secretion, suppresses glucagon release, and promotes satiety. While semaglutide is traditionally a peptide, Daewon Pharm is utilizing a specific formulation technology to enable oral delivery, aiming to improve patient compliance compared to injectable GLP-1 therapies. The sponsor's pipeline classification of the drug as a small molecule likely refers to the delivery technology or excipients used to facilitate oral absorption of the peptide active ingredient.

Other names

oral semaglutide